Holen Sie sich die Stockscreener-App
179.89
2.11%
3.71
Handel nachbörslich:
178.81
-1.08
-0.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$176.18
Offen:
$177.09
24-Stunden-Volumen:
1.49M
Relative Volume:
0.76
Marktkapitalisierung:
$26.39B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
17.21
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+4.84%
1M Leistung:
+1.98%
6M Leistung:
+42.05%
1J Leistung:
+23.02%
1-Tages-Spanne:
$175.96
$180.14
1-Wochen-Bereich:
$170.59
$180.14
52-Wochen-Spanne:
$110.03
$190.20
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
179.89 | 25.85B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,037.15 | 916.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.25 | 547.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.01 | 389.58B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
148.68 | 285.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.27 | 268.90B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Breakthrough Therapy Win Puts Litifilimab And Valuation In Focus - simplywall.st
Is Biogen (BIIB) Pricing Reflect Recent 1 Year Rebound And Long Term Weakness? - Yahoo Finance
Bank of New York Mellon Corp Sells 19,353 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Bought by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Privium Fund Management B.V. Boosts Stake in Biogen Inc. $BIIB - MarketBeat
How Biogen Inc. (BIIB) Affects Rotational Strategy Timing - Stock Traders Daily
Is Biogen (BIIB) Pricing Reflect Its Cash Flow Value After Mixed Long Term Returns - simplywall.st
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Finviz
Oppenheimer Adjusts Biogen Price Target to $225 From $205, Maintains Outperform Rating - marketscreener.com
Oppenheimer Raises Price Target for Biogen (BIIB) to $225 | BIIB Stock News - GuruFocus
Biogen Must Face Union Class Action Over Multiple Sclerosis Drug - Bloomberg Law News
Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status - Finviz
J. Safra Sarasin Holding AG Buys 6,707 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Bought by AustralianSuper Pty Ltd - MarketBeat
Biogen Can't Escape Amended Antitrust Suit Over MS Drug - Law360
FDA grants breakthrough therapy designation to Biogen’s litifilimab By Investing.com - Investing.com Australia
FDA ‘Breakthrough’ status for Biogen’s litifilimab - The Pharma Letter
FDA grants breakthrough therapy designation to Biogen’s litifilimab - Investing.com
Biogen (BIIB) Achieves Breakthrough Therapy Status for CLE Treat - GuruFocus
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options - Biogen
FDA fast-tracks Biogen lupus drug for scarring skin disease with no targeted treatment - Stock Titan
US Market Recap: Can Biogen Inc. lead its sector in growthIndex Update & Weekly Setup with ROI Potential - mfd.ru
Incredible Growth of Recombinant Dna Technology Market - openPR.com
Expert Outlook: Biogen Through The Eyes Of 11 Analysts - Benzinga
Citigroup Maintains Neutral Rating on Biogen (BIIB), Raises Pric - GuruFocus
Tau Inhibitor Market Is Going to Boom |• Eli Lilly and Company • Biogen Inc. - openPR.com
Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi - marketscreener.com
Will FDA’s Priority Review of At‑Home LEQEMBI IQLIK Dosing Change Biogen’s (BIIB) Narrative - Yahoo Finance
Biogen Surpasses Expectations with Robust Quarterly Performance and Regulatory Milestone - AD HOC NEWS
Biogen (BIIB) Valuation Check As Shares Trade Below Analyst Targets And Long Term Returns Stay Under Pressure - Yahoo Finance
AEGON ASSET MANAGEMENT UK Plc Takes Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (BIIB) Stock Analysis: A Closer Look At Its 11.98% Potential Upside - DirectorsTalk Interviews
FDA Reviews Biogen's (BIIB) Alzheimer's Drug Lecanemab-irmb Appl - GuruFocus
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - ACN Newswire
FDA Accepts LEQEMBI IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Finviz
FDA Accepts LEQEMBI IQLIK (Lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review - 富途牛牛
Eisai and Biogen Launch LEQEMBI IQLIK, FDA Review Set for May 2026 - Intellectia AI
Eisai and Biogen Announce FDA Review of LEQEMBI IQLIK, a First-of-Its-Kind At-Home Injection Treatment for Alzheimer's Disease - Quiver Quantitative
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review - Biogen
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - StreetInsider
Sector Gamma AS Has $10.57 Million Holdings in Biogen Inc. $BIIB - MarketBeat
AMF Tjanstepension AB Sells 25,636 Shares of Biogen Inc. $BIIB - MarketBeat
Assessing Biogen (BIIB) Valuation After New EU Approval For High Dose Spinraza - simplywall.st
Looking Into Biogen Inc's Recent Short Interest - Sahm
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX) and Biogen (BIIB) - The Globe and Mail
High Dose SPINRAZA EU Approval Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Postpartum Depression Drugs Market Size to Surpass USD 1.97 Billion by 2033, Due to Increasing Awareness & Fast Development of Pharmaceuticals – SNS Insider - GlobeNewswire Inc.
Priya Singhal’s Blueprint For Biogen’s Next Act - Citeline News & Insights
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Biogen Inc (BIIB) Shares Up 3.16% on Jan 21 - GuruFocus
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):